Herz
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Colchicine for the prevention of postpericardiotomy syndrome.
Postpericardiotomy syndrome (PPS) is a troublesome complication of cardiac surgery, occurring in 10-45% of cases. Accepted modalities of treatment include nonsteroidal anti-inflammatory drugs, corticosteroids, and pericardiectomy in severe cases. The optimal method for prevention of PPS has not been established. Recent trial data have shown that colchicine is efficient in the secondary prevention of recurrent episodes of pericarditis. The aim of the present study was to evaluate the possible benefit of colchicine for the primary prevention of PPS in patients after cardiac surgery. To the best of our knowledge, this is the first study addressing this issue. ⋯ Colchicine may be efficacious for the prevention of PPS in patients after cardiac surgery. Further evaluations in larger clinical trials are warranted.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
[Support of spontaneous atrioventricular conduction in patients with DDR(R) pacemakers: effectiveness and safety].
In a prospective and randomized multicenter study using a cross-over protocol we compared the efficacy and the safety of the ELA medical mode-switch algorithm (DDD/AMC = DDD to AAI) to conventional DDD stimulation in patients with spontaneous AV conduction. ⋯ The analyzed DDD/AMC mode-switch algorithm leads to a significant reduction of ventricular pacing in patients with spontaneous AV conduction or with only paroxysmal AV block. Thereby the battery lifetime is prolonged and the incidence of complications due to ventricular pacing can be reduced.
-
Randomized Controlled Trial Comparative Study Clinical Trial
[Enoximone, a new phosphodiesterase inhibitor: the spectrum of applications during heart surgery--a comparison with dobutamine].
During cardiac surgery treatment of deterioration of myocardial function is usually based on catecholamines. Development of selective phosphodiesterase-(PDE-)III-inhibitors seems to be a new aspect in treating myocardial dysfunction. Therefore the hemodynamic effects of the new PDE-inhibitor enoximone were investigated in 20 coronary surgery patients unable to be weaned from extracorporeal circulation (ECC) without pharmacological intervention (MAP less than 60 mmHg, CI less than 2.00 l/min.m2, PCP greater than 15 mmHg). ⋯ Ten minutes after weaning from ECC additional pharmacologic therapy (calcium, vasodilators, epinephrine) was necessary in eight dobutamine treated patients in contrast to four patients in the enoximone group (calcium, epinephrine). In patients with impaired myocardial performance during weaning from ECC enoximone seems to be an alternative therapy and is judged to be of some advantage compared to dobutamine application in this situation. The mechanism for improvement appears to be enhanced contractility owing to its positive inotropic effects, as well as a decrease in left ventricular outflow resistance resulting from peripheral vasodilation.